According to clinical data, the tumor microenvironment responds to IL13Rα2 CAR T therapy by boosting CD3+, CD14+, and CD15+ immune cells as well as inflammatory cytokines after locoregional CAR infusion. The gene discussed is IL13RA2; the disease is neoplasm.